^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tecentriq (atezolizumab)

    i
    Other names: MPDL3280A, RG7446, RO5541267, MPDL-3280A, RG-7446, RO 5541267, RO 554-1267, RG7446-42, RO-5541267, MPDL 3280A, RG 7446, RG744642, RG 744642, RG-744642, RO-5541267 IV, MPDL 3280A IV
    Company:
    Roche
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    1m
    Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (clinicaltrials.gov)
    P2, N=2, Active, not recruiting, National Cancer Institute (NCI) | N=240 --> 2 | Trial completion date: Oct 2027 --> Jun 2027 | Trial primary completion date: Oct 2027 --> Jan 2026
    Enrollment change • Trial completion date • Trial primary completion date • MSI-H • dMMR
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical
    1m
    Impact of Thyroid Transcription Factor-1 Expression on Outcomes of Platinum-Based Chemoimmunotherapy in Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer. (PubMed, Thorac Cancer)
    Platinum/PEM/Pembro may be a therapeutic option for TTF-1-negative non-sq NSCLC with good PS and adenocarcinoma histology, although careful management of irAE is required.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TTF1 (Transcription Termination Factor 1) • NKX2-1 (NK2 Homeobox 1)
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed
    1m
    A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Sep 2026 | Trial primary completion date: Jun 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    IL2 (Interleukin 2)
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • gemcitabine • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    1m
    A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer. (PubMed, Clin Cancer Res)
    The combinations of atezolizumab and varlilumab with/without cobimetinib were safe but neither meaningfully improved outcomes in BTC treated in the later lines. Correlative tissue studies validated preclinical work that MEK inhibition increases CD8+TILs.
    P2 data • Journal
    |
    CD8 (cluster of differentiation 8) • CD27 (CD27 Molecule)
    |
    Tecentriq (atezolizumab) • Cotellic (cobimetinib) • varlilumab (CDX 1127)
    1m
    Atezolizumab and bevacizumab plus chemotherapy versus chemotherapy in non-small cell lung cancer after tyrosine kinase inhibitor failure. (PubMed, Ther Adv Med Oncol)
    We aimed to evaluate and compare the efficacy and safety of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) versus pemetrexed plus carboplatin or cisplatin (PC) in patients with progressive NSCLC harboring EGFR, ALK, or ROS1 alterations after TKI failure. ABCP significantly improved PFS compared with PC in patients with NSCLC that progressed despite prior TKI therapy. An OS benefit was observed in patients with three or more metastatic sites.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • paclitaxel • pemetrexed
    1m
    CoLBAt: LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients (clinicaltrials.gov)
    P1, N=37, Recruiting, The Netherlands Cancer Institute | Trial completion date: Jul 2026 --> Jul 2028 | Trial primary completion date: Jul 2026 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • LB-100
    1m
    IMforte: A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (clinicaltrials.gov)
    P3, N=660, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Aug 2026 --> Feb 2028
    Trial completion date
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin)
    1m
    Pan-cancer analysis identifies immunoproteasome as the predominant survival-associated component of antigen processing machinery. (PubMed, Transl Oncol)
    In IMvigor210, immunoproteasome-high patients achieved a 3.2-fold higher response rate to atezolizumab (19.8% vs 6.2%; p=0.010). Single-cell analysis confirmed that tumor-intrinsic immunoproteasome expression correlated with increased CD8+ T cell infiltration (p=0.0014) and total immune fraction (p=0.0002). The 4-gene immunoproteasome signature demonstrates robust prognostic and predictive value across bulk sequencing, clinical trial, and single-cell platforms, warranting prospective validation as an immunotherapy biomarker.
    Journal • PD(L)-1 Biomarker • IO biomarker • Pan tumor
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CD8 (cluster of differentiation 8) • PSMB8 (Proteasome 20S Subunit Beta 8) • PSME1 (Proteasome Activator Subunit 1) • PSMB10 (Proteasome 20S Subunit Beta 10)
    |
    EGFR expression
    |
    Tecentriq (atezolizumab)
    1m
    Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial (clinicaltrials.gov)
    P3, N=336, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: Sep 2029 --> Sep 2032 | Initiation date: Jun 2026 --> Mar 2027 | Trial primary completion date: Sep 2029 --> Sep 2032
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
    2ms
    BEAT-MBM: Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • BRAF V600 • BRAF wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Cotellic (cobimetinib)
    2ms
    VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC. (PubMed, J Immunother Cancer)
    The addition of bevacizumab to chemoimmunotherapy was associated with improved survival in ns-NSCLC specifically in patients with LMs. These hypothesis-generating findings suggest that the benefit may stem from disruption of VEGF-A-driven immunosuppressive signaling in the liver, but require prospective confirmation.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • FLT1 (Fms-related tyrosine kinase 1)
    |
    EGFR wild-type • ALK wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    2ms
    AB-LATE02: Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial (clinicaltrials.gov)
    P2, N=202, Active, not recruiting, University Hospital, Montpellier | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)